Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future directions in hyperthermia biology

M W Dewhirst1

  • 1Radiation Oncology Department, Duke University Medical Center, Durham, NC 27710.

International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
|May 1, 1994
PubMed
Summary

Investigating hyperthermia treatments reveals biological sensitization of tumors is possible within current clinical temperature ranges. New drugs enhance tumor cell killing at mild hyperthermia, improving cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.

Oncogene·2021
Same author

Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.

Cancer chemotherapy and pharmacology·2017
Same author

Nitroprusside improves tumor perfusion during local 42°C hyperthermia.

Veterinary anaesthesia and analgesia·2017
Same author

Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells.

Oncogene·2014
Same author

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.

British journal of cancer·2012
Same author

A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.

British journal of pharmacology·2011

Area of Science:

  • Oncology
  • Biophysics
  • Pharmacology

Background:

  • Hyperthermia treatment for cancer faces physical limitations in achieving optimal temperatures.
  • Biological research is crucial for enhancing tumor cell sensitivity to achievable hyperthermia levels.

Purpose of the Study:

  • To explore biological strategies for sensitizing tumors to hyperthermia within the 37-42°C range.
  • To identify novel hyperthermia sensitizers and optimize drug delivery to tumors.

Main Methods:

  • Investigating drugs that exhibit cytotoxicity specifically at elevated temperatures (41-42°C).
  • Examining the use of increased tumor blood flow during heating to enhance drug delivery, including monoclonal antibodies.

Main Results:

Related Experiment Videos

  • Azo-dihydrochlorides demonstrate exquisite cytotoxicity at 41-42°C, with minimal toxicity at 37°C.
  • Utilizing increased tumor blood flow has proven effective for enhancing the delivery of therapeutic agents like monoclonal antibodies.

    • Conclusions:

    • Biological sensitization offers a promising avenue to improve hyperthermia efficacy within current clinical temperature constraints.
    • Development of targeted hyperthermia sensitizers and optimized drug delivery strategies are key for advancing cancer treatment.